Cologuard Accuracy: What the Stool DNA Test Catches and What It Misses

The Original DeeP-C Numbers

The pivotal DeeP-C trial enrolled 9,989 average-risk adults and ran the original Cologuard test alongside a fecal immunochemical test (FIT), with screening colonoscopy as the reference standard. Among the 65 participants who turned out to have colorectal cancer:

• Cologuard correctly flagged 92.3% of them
• FIT flagged 73.8%

For the 757 participants with advanced precancerous lesions (large adenomas or sessile serrated polyps at least 1 cm):

• Cologuard caught 42.4%
• FIT caught 23.8%

Specificity (the rate of correctly negative tests in people without advanced lesions) was 86.6% for Cologuard versus 94.9% for FIT. In plain terms: Cologuard finds more cancers and more big polyps, but it also flags more people who turn out to be fine.

For sessile serrated polyps measuring 1 cm or more, the gap was even wider: Cologuard caught 42.4% versus FIT's 5.1%. These flat, right-sided lesions are notoriously hard to detect, and the DNA-based approach picks them up far more reliably.

What the Next-Generation Test Changed

In 2024, the BLUE-C trial reported results for the next-generation multitarget stool DNA test (sometimes called "Cologuard Plus") in 20,176 asymptomatic adults aged 40 and older. The redesign was specifically targeted at reducing false positives while preserving cancer detection.

The headline numbers:

• Cancer sensitivity: 93.9%
• Advanced precancerous lesion sensitivity: 43.4%
• Specificity for advanced neoplasia: 90.6%
• Specificity for a non-neoplastic or negative colonoscopy: 92.7%

Cancer sensitivity ticked up slightly and advanced precancerous lesion sensitivity barely moved. The real gain was specificity, which jumped about 4 percentage points compared to the first-generation test. That translates to fewer healthy people getting a positive result and being sent for an unnecessary follow-up colonoscopy.

Compared head-to-head with FIT in the same BLUE-C cohort, the next-generation test caught significantly more cancers (93.9% vs 67.3%) and significantly more advanced precancers (43.4% vs 23.3%), while FIT had higher specificity (94.8% vs 90.6%). The trade-off didn't go away; it just got smaller.

How It Works in the 45-49 Age Group

Most of the early Cologuard data came from adults 50 and older. With the screening age now extended to 45, a 2021 study specifically evaluated the test in 816 average-risk 45- to 49-year-olds.

In this younger group, specificity ran higher than in older cohorts: 95.2% in people with non-advanced or negative findings, and 96.3% in those with completely negative colonoscopies. Sensitivity for advanced precancerous lesions was 32.7%, somewhat lower than the 42-43% seen in older populations. That's likely because precancers in younger adults tend to be smaller and earlier-stage, which all stool tests find harder to detect.

The take-home: Cologuard's specificity advantage holds up well in younger screeners, while the precancer-detection limitation is a bit more pronounced.

What Happens After a Positive Result

A positive Cologuard test triggers a colonoscopy. In real-world practice, what does that colonoscopy usually find?

A community study of 393 Medicare-age noncompliant screeners reported 14.7% Cologuard positivity, of whom 96.1% completed the follow-up colonoscopy. Among those positives:

• 8.2% had colorectal cancer
• 42.9% had advanced adenomas
• 30.6% had non-advanced adenomas
• 18.4% had a clean colonoscopy

The positive predictive value was 81.6% for any neoplasia and 51% for advanced lesions. A literature review of post-approval data reached the same general conclusion: about two-thirds of patients with a positive Cologuard turn out to have colorectal neoplasia, and roughly 1 in 3 has advanced disease. Of the people with detectable lesions, 80% have at least one right-sided lesion, where colonoscopy itself has the highest miss rates.

A separate study compared colonoscopies done with versus without knowledge of a positive Cologuard result. When endoscopists knew, 70% of those colonoscopies found adenomas or sessile serrated polyps, versus 53% when blinded, with median withdrawal times of 19 versus 13 minutes. The information itself improved the colonoscopy.

The False Positive Question

A 7 to 10% false-positive rate sounds alarming until you compare it to the alternative of missing a cancer. The question is whether a false positive means anything bad in the long run.

The LONG-HAUL cohort study followed 1,050 patients whose baseline colonoscopies came back clean, comparing those whose Cologuard had been falsely positive against those whose Cologuard had been correctly negative. After a median 4 years of follow-up, the false-positive group showed:

• No increased mortality
• No increased rate of "alarm symptoms"
• No increased aerodigestive cancer rate above general-population expectations

The conclusion was direct: a positive Cologuard followed by a clean high-quality colonoscopy doesn't justify additional aggressive testing. The DNA shedding that produced the positive result wasn't a hidden warning; it was just noise.

That doesn't mean false positives are free. Each one means another colonoscopy with bowel prep, sedation, and time off work. But it's not a marker of disease that colonoscopy missed.

Cologuard vs Colonoscopy

Colonoscopy remains the reference standard for one simple reason: it both detects and removes lesions in the same procedure. Cologuard can flag a problem; only colonoscopy can fix it. Every positive Cologuard requires a colonoscopy anyway.

So the real comparison isn't "which is more accurate." It's "given that you'll only get screened if it's tolerable, which approach catches more cancer in your specific situation?"

Modeling work suggests Cologuard every 3 years is competitive with annual FIT or 10-year colonoscopy when adherence rates are factored in. People who skip annual FIT but would do Cologuard every 3 years come out ahead. People who would happily do colonoscopy every 10 years still get more cancer prevention from colonoscopy.

The other major caveat: Cologuard isn't recommended for high-risk patients, anyone with a personal history of polyps or colorectal cancer, or people with strong family history. For those groups, colonoscopy is the only appropriate option.

What This Means If You're Considering Cologuard

If you're 45 or older, average-risk, and the choice is between Cologuard or no screening at all, the trial data is firmly on Cologuard's side: it catches over 90% of cancers and roughly half of advanced precancers, with a roughly 1-in-10 chance that a positive will turn out to be a false alarm.

If the choice is between Cologuard and colonoscopy, it depends on what you'll actually do. Colonoscopy detects more advanced precancers and removes them in the same procedure, but it requires bowel prep, sedation, and a day off. Cologuard requires shipping a stool sample and waiting for results.

Instalab's Cologuard ($599) delivers the test kit to your door, processes your sample, and reports results to you and your physician. If positive, you'll be referred to colonoscopy as the next step. The accuracy you're getting is what BLUE-C and DeeP-C measured: very strong cancer detection, moderate precancer detection, and a modest false-positive rate that doesn't appear to carry long-term harm.